Skip to main content

Table 1 Clinicopathological characteristics of 21 thyroid Burkitt’s lymphomas by meta-analysis of the literature

From: Clinicopathological features of primary thyroid Burkitt’s lymphoma: a systematic review and meta-analysis

Age (years)

6–75 (median 39.3)

Sex (Male/Female)

13/8

Clinical presentation

 Thyroid mass

17/18 (94.4%)

 Rapid growing

12/18 (66.7%)

 Dyspnea

11/18 (61.1%)

 Dysphagia

3/18 (16.7%)

 Thyrotoxicosis

1/18 (5.6%)

 Cavernous sinus syndrome

1/18 (5.6%)

 *B symptoms

4/14 (28.6%)

 Associated immuosuppressive condition

0/21 (0%)

Tumor size (mm) (median size)

20–105 (59)

Other organ involvement at diagnosis

11/21 (52.4%)

Lymph nodes involvement

11/21 (52.4%)

 Above diaphragm

7/11 (63.6%)

 Above and below diaphragm

4/11 (36.4%)

Clinical stage at presentation

 I

6/21 (28.6%)

 II

2/21 (9.5%)

 III

2/21 (9.5%)

 IV

11/21 (52.4%)

Elevated thyroid function

2/8 (25%)

Elevated TSH

1/2 (50%)

Elevated thyroglobulin

1/2 (50%)

Elevated thyroid antibody

4/8 (50%)

Hashimoto’s thyroiditis

5/7 (71.4%)

Immunohistochemistry

 CD3

0/7(0%)

 CD5

0/8(0%)

 CD10

14/14 (100%);

 CD20 (n = 18)

18/18 (100%)

 CD21 (n = 2)

0 (0%)

 CD30 (n = 2)

0 (0%)

 CD43 (n = 3)

1/3 (33.3%)

 CD79a (n = 5)

5/5 (100%)

 TDT (n = 3)

0 (0%)

 IgG (n = 1)

0 (0%)

 IgA (n = 1)

0 (0%)

 IgM (n = 1)

1/1 (100%)

 Kappa (n = 2)

1/2 (50%)

 Lambda (n = 1)

1/1 (100%)

 Bcl-2 (n = 10)

0 (0%)

 Bcl −6 (n = 6)

5/6 (83.3%)

 MUM-1 (n = 2)

1/2 (50%)

 p16 (n = 1)

1/1 (100%)

 p53 (n = 1)

0/1 (0%)

 Ki-67 labelling index (> 90%)

19/19 (100%)

 MDM2 (n = 1)

1/1 (100%)

EBER ISH

0/12 (0%)

Translocation t(8;14) (n = 12)

12/12 (100%)

CD10 + (Flow cytometry)

5/5 (100%)

Treatment

 Chemotherapy only

12/20 (60%)

 Surgery + Chemotherapy

7/20 (35%)

 Surgery + Chemotherapy + Radiotherapy

1/20 (5%)

Follow-up (months) (median)

0.5–361(46.5 m)

Clinical outcome

 Alive with complete remission

14/19 (73.7%)

 Alive with persistent disease

1/19 (5.3%)

 Dead of disease

4/19 (21.1%)

  1. EBER ISH Epstein - Barr virus Small RNAs In Situ Hybridization, FISH fluorescence in situ hybridization, LINAC Linear particle accelerator therapy
  2. *B symptoms: systemic symptoms of fever, night sweats, or weight loss